What’s Going On With Hims & Hers Stock?

Key Concepts

• Aggregator Model: A business strategy where a company acts as a central platform (like Netflix or Uber) that users voluntarily choose to access for services, effectively controlling the "front door" to a specific industry.
• Compounded Products: Medications created by pharmacists to meet the unique needs of individual patients (e.g., specific dosages not available commercially) or to address drug shortages.
• GLP-1s: A class of medications (e.g., semaglutide) used for weight loss and diabetes management.
• Peptides: Chains of amino acids that signal the body to perform specific functions; they are currently a major growth focus for Hims & Hers.
• Patent Lawsuit: A legal challenge regarding intellectual property; in this context, it refers to the dispute between Novo Nordisk and Hims & Hers over the compounding of GLP-1 medications.
• Disruptive Healthcare: A business approach that bypasses traditional insurance-based models to lower costs and increase accessibility.

---

1. Market Performance and Volatility

Hims & Hers (HIMS) has experienced significant volatility, with a year-to-date decline of approximately 67% from its 52-week high, though it has rebounded over 100% from its recent lows. The market’s negative sentiment was primarily driven by two factors:

• Regulatory Uncertainty: The expiration of FDA exemptions that allowed for the compounding of GLP-1s during shortages.
• Legal Pressure: A patent lawsuit filed by Novo Nordisk.

Travis Hoyam argues that the market misinterpreted these risks. The lawsuit was a standard patent dispute where the remedy would likely be financial rather than an injunction, and the long-term interests of both companies aligned toward collaboration rather than litigation.

2. The "Aggregator" Strategy

Hims & Hers is positioned as a healthcare aggregator. Similar to how Netflix aggregates media content, Hims & Hers aggregates healthcare demand.

• Business Tension: Traditional pharmaceutical companies prefer the legacy model (selling through doctors, pharmacies, and insurance). Hims & Hers disrupts this by operating outside the insurance ecosystem, creating inherent friction.
• Platform Evolution: The company is shifting from a simple provider to a platform that connects millions of subscribers with pharmaceutical suppliers, potentially creating a "win-win" scenario where suppliers gain access to a massive, established customer base.

3. Growth Opportunities: Peptides and Personalization

• Peptides: The potential reclassification of roughly 12 peptides from Category 2 to Category 1 would allow for widespread compounding. Because these peptides are off-patent, they represent a commodity-style growth opportunity that Hims & Hers is uniquely positioned to scale.
• Data Integration: The company is exploring ways to integrate data from wearables (Apple Watch, Garmin, Whoop) to provide personalized health treatments.
• AI in Healthcare: Unlike general-purpose AI (like ChatGPT), Hims & Hers aims to build specialized AI tools that can be updated in real-time with the latest medical information, providing a significant advantage over the traditional, slower-moving medical community.

4. Key Metrics for Investors

Investors should look beyond simple revenue growth and focus on:

• Subscriber Growth: The primary indicator of the company's ability to aggregate demand.
• Average Revenue Per User (ARPU): As the company introduces high-value products (like GLP-1s and potentially peptides) and membership models (similar to Robinhood Gold or Costco), ARPU is expected to rise.
• Membership Economics: The shift toward a subscription-based model for weight loss and other services is designed to create a recurring, high-margin revenue stream that differentiates the company from traditional pharmacy models.

5. Notable Quotes

• On Disruption: "We can't disrupt the status quo if we're living within the status quo." — Andrew Dudham (CEO of Hims & Hers), as quoted by Travis Hoyam.
• On Long-term Potential: "The potential for not just 10x, potentially even 100x in value over the next 10 to 20 years is not as crazy as it sounds." — Travis Hoyam.

6. Synthesis and Conclusion

Hims & Hers is attempting to fundamentally change the healthcare delivery model by acting as a direct-to-consumer platform that bypasses traditional insurance. While the stock remains highly volatile and faces a significant short interest, the bull case rests on the company’s ability to scale its subscriber base, successfully integrate new treatments like peptides, and leverage AI for personalized care. Travis Hoyam maintains a bullish outlook, viewing the company as a long-term "multibagger" opportunity and continuing to accumulate shares on market weakness.